In a filing, Day One Biopharmaceuticals Inc revealed its Officer ADAM DUBOW acquired Company’s shares for reported $55580.0 on Feb 18 ’25. In the deal valued at $11.96 per share,4,646 shares were bought.
Then, CHARLES YORK bought 4,370 shares, generating $52,278 in total proceeds.
Before that, JEREMY BENDER bought 12,048 shares. Day One Biopharmaceuticals Inc shares valued at $144,129 were divested by the Officer at a price of $11.96 per share.
Needham reiterated its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy in a research note published on October 09, 2024; the price target was $33. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in early August from “an Underperform” to “a Buy”. Needham also remained covering DAWN and reiterated its “Buy” recommendation on April 24, 2024. BofA Securities revised its rating on April 25, 2023. It rated DAWN as “an Underperform” which previously was an “a Buy”.
Price Performance Review of DAWN
On Tuesday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock fall -2.69% to $11.93. Over the last five days, the stock has gained 0.51%. Day One Biopharmaceuticals Inc shares have fallen nearly -5.84% since the year began. Nevertheless, the stocks have fallen -19.12% over the past one year. While a 52-week high of $18.07 was reached on 01/28/25, a 52-week low of $11.13 was recorded on 01/14/25. SMA at 50 days reached $12.52, while 200 days put it at $13.88.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 11.68, which if violated will result in even more drops to 11.43. On the upside, there is a resistance level at 12.36. A further resistance level may holdings at 12.79. The Relative Strength Index (RSI) on the 14-day chart is 43.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 77.96%. Stochastics %K at 31.89% indicates the stock is a holding.
The most recent change occurred on February 08, 2023 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
